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The depth of hematologic response has been shown to correlate with survival and organ responses for pa-
tients with light chain (AL) amyloidosis. We conducted a prospective trial of 2 cycles of induction with
bortezomib and dexamethasone on a twice a week schedule followed by conditioning with bortezomib and
high-dose melphalan (HDM) and autologous stem cell transplantation (SCT). The objectives were hematologic
responses, tolerability, and survival. Thirty-ﬁve patients were enrolled from 2010 to 2013. Of these, 30 pro-
ceeded with SCT, whereas 5 did not because of clinical deterioration during induction (n ¼ 3) or complica-
tions after stem cell collection (n ¼ 2). Two patients developed features of an autologous graft-versus-host
diseaseelike syndrome post-SCT, which responded to steroids; no other unusual complications were seen.
Treatment-related mortality occurred in 8.5% (3/35). Hematologic responses were achieved by 100% of the 27
assessable patients (63% complete response, 37% very good partial response [VGPR]) who completed the
planned treatment. By intention-to-treat, hematologic responses occurred in 77% of patients (49% complete
response, 29% VGPR). With a median follow-up of 36 months, the median overall survival and progression-
free survival were not reached. In conclusion, incorporating bortezomib into induction and conditioning
yielded a high rate of hematologic responses after HDM/SCT in patients with AL amyloidosis.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Immunoglobulin light chain (AL) amyloidosis is the most
commonly diagnosed form of systemic amyloidosis. In this
potentially lethal disorder, there is widespread deposition of
amyloid ﬁbrils, derived from monoclonal Ig light chains
associated with an underlying clonal plasma cell dyscrasia
[1]. Without effective treatment, amyloid oligomers and
ﬁbrillar deposits progressively damage organs and tissues.
Chemotherapy that ablates the underlying plasma cell
dyscrasia can arrest the deposition process and improve
survival. This was suggested in early randomized trials using
oral melphalan [2,3] but is much more evident in trials using
high-dose i.v. melphalan and autologous peripheral blooddgments on page 1450.
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ty for Blood and Marrow Transplantation.stem cell transplantation (HDM/SCT) in which much higher
hematologic response rates are seen [4-9]. In our cumulative
data of more than 600 patients treated with HDM/SCT, the
median overall survival (OS) of patients who achieve a
hematologic complete response (CR) is >13.2 years
compared with 5.9 years for those who do not, and clinical
improvement in affected organ systems occurs in 76% of
patients achieving a hematologic CR comparedwith only 39%
of those who do not. There are similar differences with
respect to improvements in performance status, quality
of life, and organ responses [10-12]. Examination of the
correlation of survival with suppression of serum free light
chain levels after a variety of treatments also supports the
importance of the depth of hematologic response [13,14].
Because hematologic CR is such a critical determinant of
treatment outcome, different strategies have been studied
that might increase the proportion of patients who ulti-
mately achieve a hematologic CR after HDM/SCT. A
randomized study examined the role of induction treatment
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SCT [15]. Following the experience in myeloma, tandem
cycles of HDM/SCT have been studied in a phase II fashion
[16,17]. Other phase II clinical trials have explored the role of
consolidation therapy with novel agents after HDM/SCT
[18,19].
Novel agents, including thalidomide [20], lenalidomide
[21,22], and bortezomib [23,24], alone or in combination
with steroids, are effective in the treatment of AL amyloid-
osis. Bortezomib, a reversible proteosome inhibitor, is an
active and rapidly acting regimen for relapsed patients with
AL amyloidosis when used alone as a single agent, in com-
bination with dexamethasone, or in combination with an
alkyating agent [25]. Furthermore, bortezomib has been
combined with HDM conditioning regimens in a pilot study
in AL amyloidosis with promising hematologic responses
without additional toxicities [26].
These considerations prompted us to conduct a pro-
spective trial of 2 cycles of bortezomib and dexamethasone
as induction therapy followed by incorporation of bortezo-
mib with HDM before SCT for the treatment of AL amyloid-
osis. The objectives of this prospective clinical trial were to
determine the safety proﬁle, hematologic response rate, and
survival of 2 cycles of induction therapywith bortezomib and
dexamethasone followed by incorporation of bortezomib
into the conditioning regimen with HDM.
METHODS
Patient Eligibility
This clinical trial was approved by the Institutional Review Board of
Boston Medical Center in accordance with federal regulations and theA Study design
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Figure 3: 
Stage I enrollment Jan 2010 to Nov 2011
Enrolled: 18
Evaluable: 15
Expected CR: 6
Observed CR: 10
17 additional 
subjects enrolled
Stage II enrollment Feb 2012 to Aug 2013
Enrolled: 35
Evaluable: 30
Expected CR: 16
Observed CR: 20
Figure 1. (A) Study design. (B) TreatmenDeclaration of Helsinki (ClinicalTrials.gov Identiﬁer: NCT01083316). Eligi-
bility for the study required a tissue diagnosis of amyloidosis with evidence
of an underlying clonal plasma cell dyscrasia and absence of evidence of
another type of amyloidosis. The plasma cell dyscrasia was assessed by
clonal dominance of plasma cells in the bone marrow and/or detection of a
monoclonal gammopathy by immunoﬁxation electrophoresis of serum and
urine proteins and/or an abnormal elevated serum free light chain con-
centration and/or ratio. Other eligibility criteria included a Southwest
Oncology Group performance status score of 2, left ventricular ejection
fraction>45%, and diffusion capacity of>50%. Patients with uncompensated
congestive heart failure, symptomatic cardiac arrhythmias, syncope, pleural
effusions refractory to medical management, or supine systolic blood
pressure <90 mm Hg were excluded, as were patients with overt myeloma
(>30% plasma cells, lytic bone lesions, or hypercalcemia) and grade 2
peripheral neuropathy. Patients requiring dialysis for end-stage renal dis-
easewere not excluded if other eligibility criteriaweremet. Modiﬁed cardiac
biomarker staging was deﬁned by the presence of brain natriuretic peptide
>100 pg/mL and troponin I >.1 ng/mL, with stage I having no elevated
biomarkers, stage II having either elevated, and stage III having both
elevated.Treatment Design
In this prospective study, newly diagnosed patients with AL amyloidosis
who met the eligibility criteria for HDM/SCT were enrolled. Patients
received 2 cycles of induction therapy with bortezomib 1.3 mg/m2 i.v. and
dexamethasone 20 mg i.v. on days 1, 4, 8, and 11 of the 21-day cycle. All
patients received prophylaxis with a proton pump inhibitor and an antiviral
medication. Bortezomibwas held for grade 3 or 4 nonhematologic toxicities,
until the toxicity resolved to grade 1 or better, for up to 2 weeks. Bortezomib
was resumed at the next lower dose level. Planned dose reductions were 1.0
mg/m2 (dose level1) and .7mg/m2 (dose level2). If the adverse event did
not resolve as deﬁned above after holding and delaying bortezomib, the
drug was discontinued. Dose escalation was not allowed.
After the 2 induction cycles, stem cell mobilization was begun within 1
to 2 weeks. Stem cells were mobilized with granulocyte colony-stimulating
factor (G-CSF) alone at 16 mg/kg/day for 3 to 4 days before stem cellly diagnosed AL amyloidosis enrolled
(n=35)
2 cycles induction therapy
3 patients removed 
due to toxicities
tem cell mobilization and collection
(n=32)
2 patients removed 
due to complications
HDM/SCT
(n=30)
3 deaths within 100 
days of SCT
Evaluable at 6 months after 
SCT (n=27)
1 death between 
6-12 months
Evaluable at 12 months after 
SCT (n=26)
reatment algorithm and consort diagram
t algorithm and consort diagram.
Table 1
Characteristics of the 35 Patients Enrolled on the Clinical Trial
Characteristic Value
Age, yr, median (range) 56 (36-70)
Patients  65 yr, n (%) 7 (20)
Female gender, n (%) 22 (63)
Performance status, median (range) 1 (0-2)
Organ involvement, n (%)
Kidney 31 (89)
Heart 19 (54)
Nervous system 7 (20)
Gastrointestinal/liver 4 (11)
Soft tissues 4 (11)
Modiﬁed cardiac biomarker stage, n (%)
I 18 (51)
II 11 (31)
III 6 (17)
24-Hour urine protein, g/24 h, median (range) 7.9 (.07-20.2)
Serum creatinine, mg/dL, median (range) .78 (.6-2.7)
Serum albumin, g/dL, median (range) 2.6 (1.4-4.3)
Brain natriuretic peptide, ng/L, median (range) 126 (14-1130)
Troponin I, ng/mL, median (range) .039 (.006-1.28)
Light chain isotype, n (%)
k 5 (14)
l 30 (86)
Bone marrow plasma cells, %, median (range) 10 (<5-20)
dFLC > 180 mg/L, n (%) 8 (23)
Time from diagnosis to enrollment, mo,
median (range)
2.1 (.7-9)
dFLC indicates difference in involved and uninvolved serum free light chain
levels.
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proceed to HDM treatment. Patients then received conditioning with bor-
tezomib at 1.0 mg/m2 i.v. on days 6, 3, þ1, and þ4 and either full HDM at
200 mg/m2 or modiﬁed HDM at 140 mg/m2 in 2 equally divided doses on
days 2 and 1 as per previously established risk-adapted criteria [2]. Stem
cells were reinfused on day 0.
All patients received prophylactic antiemetics and antimicrobial agents,
including levoﬂoxacin, ﬂuconazole, and acyclovir. All patients received
G-CSF at 5 mg/kg/day from day þ1 until neutrophil engraftment. The entire
treatment was performed as outpatient with daily visits to a day hospital
and admission to the hospital for untoward complication. Adverse events
were recorded throughout the study and were graded according to National
Cancer Institute Common Terminology Criteria for Adverse Events, version
3.0. Patients were followed for hematologic response, organ response, and
survival at 6 months and 12 months and annually thereafter.
Hematologic and Organ Response Criteria
Hematologic and organ responses were evaluated according to the
consensus criteria of the International Society of Amyloidosis published in
2005 and updated in 2010 [14,27]. Hematologic and organ responses were
measured at 6 months and 12 months and then annually thereafter HDM/
SCT. Hematologic progression was deﬁned as recurrence of plasma cell
dyscrasia after a hematologic response as per consensus criteria.
Statistical Design
The study used Simon’s 2-stage, MiniMax design with 85% power to
detect a hematologic CR of 65%, with a 5% risk of Type I error [28]. The null
hypothesis was a hematologic CR rate  40%. Accrual of 15 assessable pa-
tients was planned for the ﬁrst stage of the trial. If 6 or fewer hematologic
CRs were observed at 6 months, then the trial would be closed for futility. If
7 or more CRs were observed, then 15 additional patients would be accrued.
After the ﬁrst stage, the sample size was increased by 5 to a total of 35 to
account for nonassessable patients (Figure 1A). Estimates of primary and
secondary endpoints are reported with 95% conﬁdence intervals.
Endpoints
The primary endpoint for the study was the hematologic CR rate at 6
months after HDM/SCT. The secondary endpoints were safety and tolera-
bility, OS and progression-free survival (PFS), and organ response rate. OS
was deﬁned as the time from enrollment to the date of death from any cause.
The survival time was censored at the time of last follow-up or contact for
patients who were still alive. PFS was deﬁned as the time from the enroll-
ment to progression, initiation of second line of treatment, or death. OS and
PFS were performed using the Kaplan-Meier method, with a start date of
enrollment and a data cutoff date of November 3, 2014. A 2-sided P< .05 was
considered to be statistically signiﬁcant. All analyses were performed using
SAS 9.3 (SAS Institute Inc., Cary, NC) and R 3.1.
RESULTS
Patient Characteristics
Thirty ﬁve patients with AL amyloidosis were enrolled on
this study from January 2010 to August 2013; patient char-
acteristics are summarized in Table 1. Twenty-two (63%)
were women, and the median age was 56 years (range, 36 to
70). The performance status was Southwest Oncology Group
1 in most cases (80%), and the median number of organs
involved was 2 (range, 1 to 4). Fifteen patients (43%) had
involvement of 1 organ; most of these (13/15) had isolated
renal disease. Multiorgan involvement (2 organ system
involvement) occurred in 19 patients (54%). Renal involve-
ment was present in 30 patients (86%); 5 patients (14%) had
serum creatinine 1.5 mg/dL, but none was on dialysis.
Cardiac involvement was present in 19 patients (54%): 2 (6%
of the 35) were classiﬁed as modiﬁed cardiac biomarker
stage I, with brain natriuretic peptide and troponin I in the
normal range but echocardiographic features of amyloid
cardiomyopathy, 11 (31% of the total) had 1 of the 2 cardiac
biomarkers elevated (modiﬁed stage II), and 6 (17% of the
total) had both biomarkers elevated (modiﬁed stage III).
Thirty patients (86%) had a l clonal plasma cell dyscrasia; the
median percentage of plasma cells in the bone marrow was
10% (range, <5% to 20%).The median time from diagnosis to enrollment in the
trial was 2.1 months (range, .7 to 9). All patients were
newly diagnosed without any prior treatment, except for 1
patient who had received treatment with high-dose pulse
dexamethasone at 40 mg/day for 4 days before
enrollment.Treatment Characteristics
All 35 patients enrolled on this trial received 2 cycles of
inductionwith twice aweekbortezomib anddexamethasone.
Five patients (14%) required dose modiﬁcations and/or
discontinuationof bortezomibbecause of grade 3or 4 adverse
events: skin rash (n ¼ 1), syncope due to orthostatic hypo-
tension (n ¼ 2), and worsening renal function progressing to
end-stage renal disease (n ¼ 2). One patient (3%) required
discontinuation of dexamethasone because of grade 3 pe-
ripheral edema. Three of these patients (8.6%) didnot proceed
to stem cell mobilization because of worsening performance
status and organ function during induction.
Thirty-two patients underwent G-CSFemediated stem
cell mobilization and collection. The median number of stem
cells collected was 10.1  106 CD34þ/kg (range, 3.9 to 20.3)
with a mean number of stem cell collection sessions of 2.
Two patients did not proceed to high-dose chemotherapy
after stem cell collection because of the development of
heparin-induced thrombocytopenia in 1 and worsening of
performance status due to lumbar radiculopathy in the
second.
Overall, 30 of 35 enrolled patients (86%) were able to
proceed to HDM/SCT. Of these, 20 (67%) received full HDM at
200 mg/m2 and 10 (33%) received modiﬁed HDM at 140 mg/
m2 in 2 divided doses over 2 days. Neutrophil engraftment
occurred at a median of 10 days (range, 9 to 12) and platelet
engraftment at a median of 14 days (range, 9 to 19) after SCT.
A consort diagram (Figure 1B) summarizes the treatment
course and evaluation of patients.
Table 3
Hematologic and Organ Responses
6 Months Post-SCT
(n ¼ 27)
12 Months
Post-SCT
(n ¼ 26)
Hematologic Response
VGPR 10 6
CR 17 20
VGPRþCR (assessable) 100% 100%
VGPRþCR (intention to treat,
n ¼ 35)
77% 74%
6 Months Post-SCT
(n ¼ 27)
12 Months Post-SCT
(n ¼ 26)
24 Months Post-
SCT (n ¼ 26)
Organ Responses
Renal 6/23 (26%) 8/23 (35%) 9/16 (56%)
Cardiac 5/14 (36%) 8/14 (57%) 7/8 (87%)
Liver 0/2 (0%) 0/2 (0%) N/A*
* N/A indicates not assessable because 2 patients are not yet 2 years from
SCT.
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During induction, 9 of 35 patients (26%) experienced
grade 3 or higher nonhematologic adverse events, including
diarrhea (n ¼ 2), syncope (n¼ 4), skin rash (n¼ 1), and renal
failure (n ¼ 2). This led to dose modiﬁcations or delays in 5
patients (14%). There were no deaths during induction or
during stem cell mobilization and collection. Three deaths
occurred within 100 days of SCT, with an overall treatment-
related mortality (TRM) of 8.5%. The causes of death were
multiorgan failure due to sepsis, invasive aspergillosis, and
inﬂuenza A infection complicated by multilobar broncho-
pneumonia and respiratory failure. All 3 patients who died
had cardiac involvement: 2 were classiﬁed as modiﬁed car-
diac biomarker stage I and 1 had modiﬁed cardiac biomarker
stage III disease. Two patients who died had received 140
mg/m2 HDM and 1 had received 200 mg/m2 HDM. TRM was
20% for those who received 140 mg/m2 HDM compared with
5% for those who received 200 mg/m2 HDM; this difference
was not statistically signiﬁcant (P ¼ .2 by chi-square
comparison).
Nonhematologic adverse events of grade 3 after SCT are
listed in Table 2. Of note, none experienced grade  neu-
ropathy post-SCT. There were 11 patients with grade 3
renal adverse events, of whom 7 required renal replacement
therapy; 3were reversible after a brief course of dialysis. All 3
patients who died underwent continuous venovenous
hemoﬁltration before they died. Thus, 1 patient required
permanent hemodialysis after treatment; this patient’s
serum creatinine pretreatment was .93 mg/dL.
Two patients developed syndromes consistent with an
autologous graft-versus-host disease (GVHD)-like process.
The ﬁrst of these developed fever, skin rash, pancytopenia,
and diarrhea on day þ60 after SCT. An Epstein-Barr viremia
was detected, and a bonemarrow biopsywas consistent with
a polyclonal post-transplant lymphoproliferative disorder. A
skin biopsy demonstrated a lymphocytic inﬁltrate consistent
with grade II GVHD. After treatment with rituximab and
corticosteroids, these features resolved completely. The
second of these patients developed copious diarrhea (up to 6
L/day) around day þ21 post-SCT, with elevated hepatic
transaminases, thrombocytopenia, and acute kidney injury.
Biopsy of the colon was consistent with GVHD, with crypt
abscesses and focal crypt apoptosis; workup for an infectious
etiology of the diarrhea was negative. This patient was
treated with high-dose parenteral steroids and oral bude-
sonide with improvement in 4 days and complete resolution
after 2 weeks. One patient developed spontaneous splenic
rupture on day þ16 that was treated successfully with
splenic artery embolization.
Hematologic Response
Hematologic responses are summarized in Table 3. He-
matologic CR was achieved in 63% (17/27) at 6 months afterTable 2
Adverse Events after HDM/SCT (Grade  3) in 30 Patients
Adverse Event Number of Patients (%)
Nausea or vomiting 6 (20)
Diarrhea 15 (50)
Stomatitis 1 (3)
Hepatic 7 (23)
Renal 11 (37)
Cardiac 18 (60)
Febrile neutropenia 7 (23)
Sepsis 4 (13)
Skin rash 3 (10)SCT and 77% (20/26) at 12 months after SCT in assessable
patients. By intention-to-treat, the CR ratewas 49% (17/35) at
6 months and 57% (20/35) at 12 months. Hematologic very
good partial response (VGPR) occurred in an additional 10
patients at 6 months (37% of 27 assessable patients) and 6
patients at 12 months (23% of 26 assessable patients), which
translated to 29% and 17%, respectively, for an intention-to-
treat analysis. Thus, at the prespeciﬁed time point of 6
months, the overall response rate (VGPR or better) was 77%
of enrolled patients (27/35) and 100% for the 27 patients who
completed planned therapy and were assessable at 6
months. The 95% conﬁdence interval for detecting 65% CR
rate was (.50-.78), with a P ¼ .003, suggesting the success of
this clinical trial at the expected rate.
OS and PFS
The median follow-up of the surviving patients was 36
months (range, 14.8 to 59.1), and the data collection for the
median PFS and OS is ongoing. The Kaplan-Meier survival
curves for the OS and PFS are shown in Figure 2. The median
OS and PFS are not reached. Five patients died during the
follow-up period, including 3 within 100 days of SCT
(included in TRM). One of these patients died within a year of
SCT because of worsening of congestive heart failure and
disease progression in the heart. Another of these patients
died from Klebsiella pneumoniae sepsis and multiorgan fail-
ure; however, this patient did not proceed to SCT after in-
duction therapy because of syncope. Death occurred after 30
months of enrollment on the trial.
Three patients who achieved a VGPR after SCT progressed
requiring additional treatment at a median time of 38
months (range, 36.1 to 37.8). Second-line treatment included
ixazomib on a clinical trial, bortezomib, or lenalidomide. The
patient treated with ixazomib achieved a CR after second-
line treatment. The other 2 patients treated with bortezo-
mib and lenalidomide did not achieve a hematologic
response. There was no progression or relapse of plasma cell
dyscrasia among those with CR after SCT.
Organ Response
Organ responses were also evident after SCT (Table 3).
Organ response rates of the assessable and surviving patients
gradually increased from 6 months to 12 months to 24
months after SCT. Cardiac and renal responses were more
evident than reduction in hepatomegaly or alkaline
Figure 2. OS and PFS by Kaplan-Meier analysis with 95% conﬁdence intervals (dotted lines).
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response (reduction in proteinuria >50% without worsening
of creatinine or creatinine clearance by more than 25%)
occurred in 26% to 35% to 56% at 6months,12months, and 24
months, respectively, after SCT. Similarly, cardiac response
occurred in 36% to 57% to 87% at 6months,12months, and 24
months, respectively, after SCT.
DISCUSSION
This is one of the ﬁrst prospective trials of induction
therapy with bortezomib and dexamethasone, with incor-
poration of bortezomib into a HDM conditioning regimen for
autologous SCT for newly diagnosed patients with AL
amyloidosis. This prospective trial was designed after a pilot
study of 10 patients in which bortezomib was incorporated
into the conditioning regimen, with no evidence of unusual
toxicities [26]. The goal of the current trial was to investigate
the safety and efﬁcacy of the combined regimen, with the
objective of increasing the CR rate and survival of transplant-
eligible patients with AL amyloidosis. It was recognized that
eligibility for SCT by itself is a favorable prognostic factor in
AL amyloidosis [29].
Hematologic responses in this trial were unprecedentedly
high. A hematologic VGPR or greater at 6 months was ach-
ieved in 77% of the 35 enrolled patients but was 100% for the
27 patients who completed all planned therapy. At the me-
dian follow-up time of 36 months, estimated 5-year OS rate
was 84% and PFS, 66%. This compares favorably with our
prior reports of 5-year OS rates of 58% and PFS of 37% [4].
The role of induction therapy has not beenwell studied in
AL amyloidosis because plasma cell burden in this disease is
low and therefore induction therapy is not necessary before
HDM/SCT. The purpose of induction therapy with bortezo-
mib in this clinical trial was to assess if rapid reduction of
amyloidogenic precursor light chain levels can lead to
improvement in organ dysfunction before HDM/SCT, making
this aggressive treatment more tolerable. Use of induction
treatment before HDM/SCT have been reported in a few
studies with negative results. Pretreatment with 2 cyclesof oral melphalan and prednisone before HDM/SCT was
studied in a randomized phase III clinical trial showing no
improvement in hematologic responses, OS; in fact, a sur-
vival disadvantage was found for patients with cardiac
involvement [15]. Similarly, administration of infusional
chemotherapy VAD (vincristine, Adriamycin, and dexa-
methasone) before HDM/SCT did not improve hematologic
responses [30]. Although the role of novel agents like bor-
tezomib before HDM/SCT in AL amyloidosis was unknown at
the time of trial design, a recently published randomized,
phase III, single-center study has shown a beneﬁt for borte-
zomib induction in CR rate and survival [31]. Although their
CR rate at 12 months of 70% appears to be slightly lower than
ours, additional randomized multicenter trials will be
required to determine optimal timing and use of bortezomib
with HDM/SCT.
Bortezomib has also been studied as consolidation after
HDM/SCT for those achievinga less thanVGPR. Twenty-twoof
40 patients received post-SCT bortezomib treatment, with
58% achieving a CR and 55% achieving an organ response [18].
TRM on this trial was 8.5% (3/35). Two of the 3 TRMs
occurred because of infections, invasive aspergillosis, and
inﬂuenza A complicated with bronchopneumonia. Further-
more, there were unusual complications in 2 cases of an
autologous GVHD-like syndrome occurring within 100 days
of SCT that responded to high doses of steroids with full re-
covery. After an occurrence of the second case of this unusual
complication, the trial was halted by the investigators, and an
external data safety monitor was asked to review the ﬁrst 19
subjects enrolled. Based on the monitor’s recommendations
to the investigators and to the institutional review board, the
informed consent was modiﬁed and the trial was resumed.
The pathogenesis of this autologous GVHD-like syndrome
remains unclear; however, several mechanisms can be
postulated with this novel induction and conditioning
regimen including bortezomib in this less heavily pretreated
patient population. Increased occurrence of this syndrome
has been recently seen in myeloma patients undergoing
HDM/SCTas well [32]. This syndrome occurred at a rate of 6%
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to alteration in autoreactive T cells in the collected graft
because of the proximity of induction bortezomib to stem
cell collection or to post-SCT immune modulation with bor-
tezomib (day þ1 and day þ4, respectively), leading to
depletion of regulatory T cells after the conditioning regimen
[33]. Further studies are needed to elucidate the exact
mechanism of this unusual, nonfatal complication [34]. We
encourage other clinicians to be aware of this potential side
effect in regimens incorporating bortezomib and alkylating
agents together in SCT.
Five of 35 patients (14%) were eligible to receive SCTat the
time of enrollment and did not proceed to because of com-
plications causing deterioration in clinical condition during
induction. Bortezomib, in this trial, was administered twice a
week; other studies have suggested that bortezomib is better
tolerated in AL amyloidosis patients when given on a weekly
schedule [35]. Twenty-six percent of patients experienced
grade 3 nonhematologic adverse events during induction,
leading to dose delay and modiﬁcation in 14%. It is possible
that side effects could be ameliorated by weekly dosing and
by subcutaneous route of administration [36].
Grade  3 cardiac adverse events occurred in 60% of
patients, and all 3 deaths from TRM had evidence of cardiac
involvement. Severity of cardiac involvement remains the
most important determinant of tolerability of HDM/SCT in AL
amyloidosis. Appropriate patient selection with New York
Heart Association classiﬁcation; functional measures of ex-
ercise capacity, including stair climbing ability and a formal
cardiopulmonary exercise testing; and a risk-adapted treat-
ment approach (ie, plerixafor with abbreviated G-CSF mobi-
lization [37]) can lead to safe delivery of HDM/SCT in patients
with AL amyloidosis and cardiac involvement [38,39]. A
strategy to delay SCT after induction therapy to allow for
improvement in cardiopulmonary status is appealing; how-
ever, this was not the intent of this particular clinical trial.
Organ responses were delayed relative to hematologic
responses in this trial and improved from 6 months to 12
months to 24 months after SCT. Cardiac organ responses
were signiﬁcantly higher than we have previously reported,
due to the use of newer response criteria from 2010 related
to cardiac biomarkers and not echocardiographic ﬁndings
[14]. It was surprising to note the absence of hepatic re-
sponses even at 1 year after SCT, perhaps because of the
small number of patients with hepatic involvement, because
this differs from our prior observations [11].
This study has several limitations. The sample size is too
small to allow patient stratiﬁcation based on cardiac
biomarker staging or other subgroup analyses. With a me-
dian follow-up of 36 months, median OS and PFS were not
reached. As noted above, our study was not designed to tease
out the relative beneﬁts of bortezomib in induction versus
conditioning. Nonetheless, the promising results of this and
other studies using bortezomib with HDM/SCT suggest that
bortezomib does improve outcomes. For transplant-eligible
patients with AL amyloidosis, no other regimens have pro-
duced comparable hematologic and organ responses and
survival. Future multicenter, randomized, phase III trials are
required to compare outcomes of the best transplant and
nontransplant regimens.
In conclusion, incorporating bortezomib into induction
and conditioning yielded a high rate of hematologic response
with tolerable toxicity. Five patients (14%), who were eligible
for SCT at enrollment, did not proceed to SCT because of
clinical deterioration during induction treatment. There wasno negative impact of bortezomib induction on stem cell
collection or engraftment. The unusual occurrence of 2 cases
of GVHD-like syndrome requires further investigation of the
mechanism and potential association with this particular
regimen.
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